HK Stock Market Move | EAST BUY (01797) opened more than 3% lower. Four popular anchors successively announced their resignations. Yu Minhong admits that there have been deviations in the management approach.
(01797) opened more than 3% lower, as of the time of writing, it has fallen 3.49% to HKD 26.52 with a turnover of HKD 10.92 million.
EAST BUY (01797) opened more than 3% lower, as of press time, it fell by 3.49% to HKD 26.52, with a turnover of HKD 10.9262 million.
On the news front, on April 25th, four popular anchors under EAST BUY, Ming Ming, Tian Quan, Zhong Can, and Lin Lin, announced their resignations one after another. On that day, Ming Ming, Tian Quan, and other anchors mentioned in their posts that they resigned due to changes in the company's management and philosophy. According to the media reports, a large number of users on social media posted requesting to withdraw from EAST BUY membership. Some users mentioned that they were canceling their membership because the anchors were leaving.
Regarding the collective resignation of the anchors, Yu Minhong responded in a live broadcast on April 25th, admitting that there were deviations in the company's management methods after the management adjustment. In addition, Yu Minhong stated that this departure of core anchors will not affect the daily operations, product supply chain, and user service system of EAST BUY, and the platform will continue to carry out live broadcasting business as usual.
Related Articles

HK Stock Market Move | DAISHOMICROLINE(00567) rose by over 20% and is planning to change its name to "Jin'anju Intelligent Technology Group".

New Stock News | Jiangxi Biopharmaceutical IPO prospectus invalid

Build a comprehensive solution in the field of respiratory medicine, from drugs to medical devices! CF PHARMTECH (02652) successfully completes the first clinical trial of bronchial valves (EBV) in patients with severe emphysema.
HK Stock Market Move | DAISHOMICROLINE(00567) rose by over 20% and is planning to change its name to "Jin'anju Intelligent Technology Group".

New Stock News | Jiangxi Biopharmaceutical IPO prospectus invalid

Build a comprehensive solution in the field of respiratory medicine, from drugs to medical devices! CF PHARMTECH (02652) successfully completes the first clinical trial of bronchial valves (EBV) in patients with severe emphysema.






